<DOC>
	<DOCNO>NCT01343303</DOCNO>
	<brief_summary>The purpose study evaluate safety multiple oral dos JNJ-39439335 ass JNJ-39439335 absorbed ( take ) , distribute , metabolize ( break ) , eliminate body ( referred pharmacokinetics ) osteoarthritis patient . This study also assess effectiveness JNJ-39439335 pain .</brief_summary>
	<brief_title>A Multiple Dose Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics JNJ-39439335 Patients With Osteoarthritis</brief_title>
	<detailed_description>This double-blind ( patient study staff know identity assign treatment ) , randomize ( assignment 1 3 treatment group chance , like `` flip coin '' ) , placebo-controlled , multiple dose study conduct two clinical site . Up 42 patient osteoarthritis knee enrol 3 cohort ( Cohort 1 3 ) . Additional cohort ( 14 patient per cohort ) may add completion Cohort 3 . The study consist eligibility screening , treatment phase , 4 follow-up visit . The study duration patient approximately 10 week . Patients safety closely monitor study review adverse event , electrocardiogram , vital sign ( include oral temperature ) , clinical laboratory test , physical examination . During specify study visit , blood sample collect pharmacokinetics , pharmacodynamics ( inpatient patient ) , pharmacogenomic ( optional ) evaluation JNJ-39439335 . The effectiveness JNJ-39439335 evaluate assess pain use 11-point numerical rating scale Western Ontario McMaster Osteoarthritis Index . In Cohort 1 2 , patient take study medication orally , twice day 21 day . The treatment group Cohort 1 JNJ-39439335 10 mg , naproxen 500 mg every 12 hour , placebo . The treatment group Cohort 2 JNJ-39439335 25 mg , naproxen 500 mg every 12 hour , placebo . The treatment group Cohort 3 determine base result Cohort 1 2 .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Nonsmoker &gt; = 6 month prior first dose body mass index ( BMI ) &lt; = 36 kg/m2 Meet American College Rheumatology ( ACR ) clinical classification criterion osteoarthritis knee meeting least 3 follow : age &gt; 50 , morning stiffness &lt; 30 minute , crepitus active motion , bony tenderness , bony enlargement , palpable warmth synovium Has Functional Class IIII osteoarthritis ( OA ) knee continue OAknee joint pain &gt; = 5 days/week x 3 month prior screen , take nonopioid analgesic OA knee pain daily &gt; =5 day prior screen benefit Otherwise healthy base physical exam , medical history , vital sign , 12lead electrocardiogram ( ECG ) , clinical laboratory test Women must postmenopausal surgically sterile . Oral temperature &gt; 37.5 deg C Screening Day 1 Failure burn prevention measure quiz Screening patient occupation hobby routinely expose situation could sustain burn orthopedic and/or prosthetic device target knee joint Significant pain outside target knee , include significant hip back pain ( bilateral knee OA permit ) Unable discontinue prior analgesic medications/nonsteroidal antiinflammatory drug ( NSAIDS ) paracetamol study Surgical intervention pain within 3 month prior screen plan surgical intervention study History prior diagnosis inflammatory arthritis ( include rheumatoid arthritis ) Treatment local corticosteroid injection viscosupplementation target joint , use oral intramuscular corticosteroid , within 3 month prior Screening History active peptic ulceration , active dyspepsia , gastrointestinal bleeding , Crohn 's disease , ulcerative colitis , chronic diarrhea esophageal , gastric duodenal ulcer within 3 month prior screen condition , Investigator 's opinion , precludes use NSAID .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Osteoarthritis , knee</keyword>
	<keyword>knee pain</keyword>
	<keyword>pain measurement</keyword>
</DOC>